Clinical study of the PROMETA Treatment Program for alcohol dependence at Center for Drug and Alcohol Program’s (CDAP) Charleston Alcohol Research Center (CARC) at the Medical University of South Carolina (MUSC), Charleston, SC
• Raymond Anton, MD; Hugh Myrick, MD; and Robert Malcolm, MD • 60-subject, double-blind, placebo-controlled study; withdrawal symptoms, alcohol use and abstinence as endpoints • Brain imaging (brain responsiveness to alcohol cues and craving activation)
• Study presented at RSA, July 2008
Clinical study of the PROMETA Treatment Program for methamphetamine dependent subjects at Research Across America, Dallas, TX
• Harold C. Urschel III, MD, MMA; psychiatrist • 88-subject, randomized, double-blind, placebo-controlled study • Changes in neurocognitive functioning during early abstinence, reduced cravings, drug-free days, efficacy of perceived disability and effect on drug-related sexual practices as endpoints
• Study presented at CPDD, June 2006.
Evaluation of a new alcohol, cocaine and methamphetamine treatment with court diverted individuals with Southern University, Baton Rouge, LA
• Murelle Harrison, PhD • 30-subject, single-site, open-label, intent-to-treat; self-reported drug use, weekly urine screens, test feasibility and usefulness of the data collection instruments as endpoints
• Study COMPLETED: July 2007
Evaluation of the PROMETA Treatment Program for alcohol dependence at Cedars-Sinai Medical Center, Los Angeles, CA
• Jeffrey Wilkins, MD; Vice Chairman, Department of Psychiatry and Mental Health • 30-subject, run-in, open-label, single-site study w/ 16 week follow-up on days to first drink, days drinking, days heavy drinking, cravings and QOL as endpoints • Study presented at RSA July 2007: Cognitive Performance of Subjects Undergoing Flumazenil, Hydroxyzine, and Gabapentin Treatment of Alcohol Dependence
• Study presented at INS, June 2007
An open-label study on the safety and clinical effectiveness of the PROMETA Treatment Program in treating methamphetamine dependence at Research Across America, Dallas, TX
• Harold C. Urschel III, MD, MMA; psychiatrist • 50-subject open-label study; retention, cravings, weekly urine screens, number of days abstinent as endpoints • Study presented at Urschel open label CPDD June 2006: Safety and clinical effectiveness of Prometa for treating methamphetamine dependence • Mayo Clinic Proceedings October 2007: Open-Label Study of a Proprietary Treatment Program Targeting GABAA Receptor Dysregulation in Methamphetamine Dependence
Evaluation of the PROMETA Treatment Program for treatment of alcohol dependence at Cedars-Sinai Medical Center, Los Angeles, CA
• Jeffrey Wilkins, MD; Vice Chairman, Department of Psychiatry and Mental Health • 80-subject, randomized, double-blind, placebo-controlled study of the Prometa Treatment Program on neurocognitive function and cravings in alcohol dependence.
• First subject in: April 2007
Clinical study of the PROMETA Treatment Program for alcohol dependence at Institute of Addiction Medicine in Philadelphia, PA
• Jenny Starosta, PhD and Joseph Volpicelli, MD • 120-subject, randomized, double-blind, placebo-controlled study; changes in neurocognitive functioning, reduced cravings, subject retention, self-report and biomarkers of alcohol use, safety and efficacy as endpoints
• First subject in: March 2007
Clinical study for testing efficacy for treatment of methamphetamine dependence at UCLA’s Integrated Substance Abuse Program (ISAP), Los Angeles, CA
• Walter Ling, MD; board-certified neurologist and psychiatrist • 120-subject, multi-site, randomized, double-blind, placebo-controlled study; abstinence and preventing relapse as endpoints
